Springer Nitric Oxide and Cancer: Pathogenesis and Therapy

Product Description Advances in Nitric Oxide and Cancer is a volume that serves to give the latest research on nitric oxide (NO) and cancer. More specifically, the volume reviews significant advances in the application of NO-mediated drugs. The volume explores nitric oxide and its relationship to cancer spanning from its roles in the pathogenesis, prognosis, gene and protein modifications, regulation of resistance to cytotoxics, and therapeutic applications. With chapters written by leading experts, the volume addresses the burgeoning interest in a rapidly advancing field and provides a valuable resource to scientists who have initiated research as well as clinical investigations in their laboratories on the various roles of NO and cancer. Review “It describes the current perceptions on the role of NO. in cancer and a possible therapeutic application of NO. in the clinical practice. … The book also presents several mechanisms of multiple effects and potential of NO. for therapeutic use under optimal conditions. It can be recommended to all readers who are interested in the pathogenesis and therapy of cancer.” (Darina Slamenova, Neoplasma, Vol. 62 (6), 2015) From the Back Cover Nitric Oxide and Cancer: Pathogenesis and Therapy provides the latest research and applications of nitric oxide (NO) in cancer written by experts in the field. The volume reviews significant advances in the biochemical and molecular biology of NO-mediated effects in cancer. Additionally, it explores NO and its relationship to cancer, delineating its roles in the pathogenesis, prognosis, gene and protein modifications, regulation of resistance to cytotoxic drugs and immunotherapies, and potential therapeutic applications. Nitric Oxide and Cancer addresses the burgeoning interest in a rapidly advancing field, and serves as both a valuable resource for scientists, clinicians, students, and health professionals and a reference for teaching and educational purposes. About the Author Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals.